Ann: CORE NK Platform Phase 1 Clinical Data Presentation, page-28

Thanks@FreeBobby2002. To whoever the clown was who got my earlier post moderated, I refer you to Jen's comments at 9:50 and her answer to my question at 15:45.

To reiterate, these results are particularly encouraging as all of the patients in this trial had failed multiple lines of therapy and in the case of the solid tumours had metastatic disease - in other words on death's door. In response to my question, Jen said the prognosis for these patients in the absence of NK therapy would likely be 3-6 months to live. So, certainly impressive results both from a safety (what the trial was designed to assess) and an efficacy signal perspective.